Evaluation of 0.1% and 1% atropine eyedrops in cats: A comparative study of tolerance, stability, and efficacy.
compounded formulation
feline
mydriasis
ocular pharmacology
ocular tolerance
pupil dilation
Journal
Veterinary ophthalmology
ISSN: 1463-5224
Titre abrégé: Vet Ophthalmol
Pays: England
ID NLM: 100887377
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
revised:
16
07
2024
received:
20
05
2024
accepted:
08
08
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
23
8
2024
Statut:
aheadofprint
Résumé
Investigate the tolerance, stability, and efficacy of topical 0.1% and 1% atropine in cats. Six cats underwent two trials separated by a 2-week washout period. One drop of artificial tears was placed in one randomly selected eye (control), and one drop of either 0.1% atropine (Trial I) or 1% atropine (Trial II) was placed in the other eye. Immediate adverse effects were recorded for severity (0-3) and duration (seconds). Horizontal pupil diameter (HPD), pupillary light reflexes (PLRs), intraocular pressure (IOP), Schirmer tear test-1 (STT-1), and heart rate (HR) were monitored at baseline then 8 h post-administration. PLRs were assessed for a total of 72 h. Stability was assessed weekly for 1 month in room temperature and refrigerated conditions, evaluating solution clarity, pH, and drug concentrations. Adverse effects had a significantly lower severity score and shorter duration with 0.1% versus 1% atropine (severity 1.2 ± 0.4 vs. 2.5 ± 0.5, p = .010; duration 107.5 ± 53.3 vs. 293.3 ± 106.5 s, p = .009). HPD was significantly greater than baseline measurements as early as 40 min for both atropine formulations. Pupils were non-responsive for a significantly shorter duration with 0.1% versus 1% atropine (median 7 h vs. 47.5 h, p = .031). Compared with control eyes, IOP was significantly elevated by 1% atropine (p = .021) but not 0.1% atropine (p = .502). No significant differences were noted in STT-1 and HR measurements. Both solutions were stable in room temperature and refrigerated conditions for 1 month. Diluted 0.1% atropine was stable and better tolerated by cats, offering a potential alternative to feline patients that experience adverse effects from topical 1% atropine.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Veterinary Ophthalmology published by Wiley Periodicals LLC on behalf of American College of Veterinary Ophthalmologists.
Références
Herring IP. Part 4: Mydriatics/Cycloplegics, Anesthetics, and Tear Substitutes and Stimulators. In: Gelatt KN, Ben‐Shlomo G, Gilger BC, Hendrix VH, Kern TJ, Plummer CE, eds. Veterinary Ophthalmology. 6th ed. John Wiley & Sons; 2021:435.
Greenberg S, Plummer C, Maisenbacher H, Friary J, Berg A. The effect of topical ophthalmic 1% atropine on heart rate and rhythm in normal dogs. Vet Ophthalmol. 2015;18(2):105‐108.
Davis JL, Stewart T, Brazik E, Gilger BC. The effect of topical administration of atropine sulfate on the normal equine pupil: influence of age, breed and gender. Vet Ophthalmol. 2003;6(4):329‐332.
van Alphen GW, Angel MA. Activity of prostaglandin E, F, a and B on sphincter, dilator and ciliary muscle preparations of the cat eye. Prostaglandins. 1975;9(2):157‐166.
Chou AC, Shih YF, Ho TC, Lin LL. The effectiveness of 0.5% atropine in controlling high myopia in children. J Ocul Pharmacol Ther. 1997;13(1):61‐67.
Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology. 2012;119(2):347‐354.
Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014;157(2):451‐457.e1.
Zhao Y, Feng K, Liu RB, et al. Atropine 0.01% eye drops slow myopia progression: a systematic review and meta‐analysis. Int J Ophthalmol. 2019;12(8):1337‐1343.
Stadtbäumer K, Frommlet F, Nell B. Effects of mydriatics on intraocular pressure and pupil size in the normal feline eye. Vet Ophthalmol. 2006;9(4):233‐237.
Gelatt KN, Boggess TS, Cure TH. Evaluation of mydriatics in the cat. J Am Anim Hosp Assoc. 1973;9:283‐287.
Lahdes K, Kaila T, Huupponen R, Salminen L, Iisalo E. Systemic absorption of topically applied ocular atropine. Clin Pharmacol Ther. 1988;44(3):310‐314.
Kovalcuka L, Nikolajenko M. Changes in intraocular pressure, horizontal pupil diameter, and tear production during the use of topical 1% cyclopentolate in cats and rabbits. Open Vet J. 2020;10(1):59‐67.
Selk Ghaffari M, Javadzadeh R, Rajaei SM. Effects of two concentrations of topical tropicamide on the Schirmer tear test in clinically normal cats. J Feline Med Surg. 2016;18(12):965‐969. doi:10.1177/1098612X15602524
Sriwidodo S, Kurniawan Syah IS, Maksum IP, Subroto T, Zasvia U, Umar AK. Stabilization of eye drops containing autologous serum and recombinant human epidermal growth factor for dry eye syndrome. J Adv Pharm Technol Res. 2020;11(4):184‐188.
Cieri UR. Determination of atropine (hyoscyamine) sulfate in commercial products by liquid chromatography with UV absorbance and fluorescence detection: multilaboratory study. J AOAC Int. 2003;86(6):1128‐1134.
Pe'er O, Weiss K, Arad D, Sebbag L, Ofri R. Florid spot keratopathy in Israel. 100 canine and feline cases. European College of Veterinary Ophthalmologists; 2024 (abstract).
Gomes FE, Bentley E, Lin TL, McLellan GJ. Effects of unilateral topical administration of 0.5% tropicamide on anterior segment morphology and intraocular pressure in normal cats and cats with primary congenital glaucoma. Vet Ophthalmol. 2011;14 Suppl 1(Suppl 1):75‐83.
Kovalcuka L, Birgele E, Bandere D, Williams DL. Comparison of the effects of topical and systemic atropine sulfate on intraocular pressure and pupil diameter in the normal canine eye. Vet Ophthalmol. 2015;18(1):43‐49.
Beckwith‐Cohen B, Elad D, Bdolah‐Abram T, Ofri R. Comparison of tear pH in dogs, horses, and cattle. Am J Vet Res. 2014;75(5):494‐499.
Regnier A. Part 1: Ocular Drug Delivery. In: Gelatt KN, Ben‐Shlomo G, Gilger BC, Hendrix VH, Kern TJ, Plummer CE, eds. Veterinary Ophthalmology. 6th ed. John Wiley & Sons; 2021:349.
Sebbag L, Moody LM, Mochel JP. Albumin levels in tear film modulate the bioavailability of medically‐relevant topical drugs. Front Pharmacol. 2019;10:1560.
Sebbag L, Broadbent VL, Kenne DE, Perrin AL, Mochel JP. Albumin in tears modulates bacterial susceptibility to topical antibiotics in ophthalmology. Front Med (Lausanne). 2021;8:663212.
Sebbag L, Soler EA, Allbaugh RA, Mochel JP. Impact of acute conjunctivitis on ocular surface homeostasis in dogs. Vet Ophthalmol. 2020;23(5):828‐833.
Colitz CM. Feline uveitis: diagnosis and treatment. Clin Tech Small Anim Pract. 2005;20(2):117‐120.
Townsend WM. Canine and feline uveitis. Vet Clin North Am Small Anim Pract. 2008;38(2):323‐346. vii.
Cirla A, Drigo M, Ballerini L, Trucco E, Barsotti G. Effects of pupil dilation with topical 0.5% tropicamide on retinal vascular parameters assessed by VAMPIRE® software in healthy cats. Res Vet Sci. 2023;160:50‐54.